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Abstract Drug licensing and drug safety monitoring for
standard chemical entities have been established and are
routinely used. These have resulted in a solid foundation of
knowledge from which confident therapeutic decisions can be
made. For many chemical entities, this advanced level of
experience is also present for the generic products. The expertise
surrounding the development of biosimilar competitor versions
is increasing and progress is encouraging. To address the re-
engineering and comparability complexities of biosimilars, the
European Union imposed a requirement that risk management
plans be included in the medications’ marketing applications.
This paper summarizes and discusses the circumstances
complicating the public’s view of drug safety, historical incidents
during the transition from innovative to competitor products, as
well as retrospective assessments of the development and post-
marketing experiences thus far with two biosimilars. Through
assessing the market entries and post-marketing experiences of
biosimilars used in oncology, the healthcare field can better
prepare for the next wave of comparator-products: biosimilar
monoclonal antibodies.
Keywords Risk management . Drug licensing . Drug
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Introduction
Discoveries surrounding disease states and their drug
treatments are becoming increasingly complex. Conveying
a risk-benefit ratio to patients was already a cumbersome
task and as the medical field evolves, this task is becoming
even more difficult. Many reasons lead to the discrepancy
between the expectations of patients (a new, expensive drug
will be better) and the harsh realities of physicians, other
healthcare professionals and regulators. Many of these
could be due to the public’s lack of knowledge surrounding
the complexity of pharmaceutical agents and the safeguard-
ing of their use. Several of these discrepancies shall be
discussed within this paper including: the process of drug
licensing and why drug safety monitoring programs, like
the creation of risk management plans, exist. Additionally,
issues more closely related to the field of oncology itself,
such as the development of biosimilars and use of
monoclonal antibodies, are also covered.
The safety myth of new drugs
The development process for new medicines requires an
extraordinary amount of time and work and all steps must
be carefully planned. Looking past the complexity of
pharmaceutical science itself, regulatory authorities that
oversee the introduction of new drugs to the market require
extensive documentation. The ability of innovators to
foresee problems and work pro-actively to avoid these
from happening is pivotal; avoiding risky situations when
developing a newly innovative product will help simplified
market-entry process.
Regulators require a minimum success standard prior to
accepting claims that a drug is efficacious in a given
population. Therefore, to circumvent compromising the
new compound’s reputation (and the profitability and
shareholders’ value), appropriate inclusion and exclusion
criteria are determined to optimise the trial’s patient
population and design during the development phase. The
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main question that a new, innovative medication trial strives
to answer could be summarized by some as: Will the drug
do what it is designed to do in the smaller-sized test
population of patients with a certain disease (with as few
adverse side effects as possible)? By carefully selecting a
patient population based on their personal health status
(disease state status) and history, the trial is tailored to the
target population. To some, this may seem like obfuscation
of the true results; however, these conditions are necessary
since the question-to-be-answered about the medication’s
efficacy is usually concerning treatments within certain
patients. In many pre-licensing trials, many side effects may
occur in a frequency not much different from that of
placebos. It is an exciting time for innovators if their new
medicinal agents overcome these obstacles and the medi-
cines are granted market approval. They are then finally
able to provide an answer to that previously contemplated
central question by confidently stating: yes, this medication
works and the potential side effects from it are worth the
positive benefit seen from the desired mechanism in the
trial population, but not necessarily in the real-life popula-
tions. This difference is often referred to in healthcare as a
difference of efficacy (how well a medication works under
ideal, controlled settings such as a trial) and effectiveness
(how the medicine functions under real-world conditions).
As a new medication with an unscathed reputation enters
the market, it brings with it the known knowledge gaps
from the fine-tuned trials and these questions can only be
answered through future use. However, once the drug is
used in everyday conditions, outside the protective confines
of the carefully selected study criteria, the safety in real life
situations may vary when compared to the carefully
selected trial population in terms of comorbidities, co-
medication, age, pregnancy etc. For some drugs, these new
adverse effects are found quickly and tumultuous cases lead
may prompt market removal of the medications [1, 2]. For
others, clarification of the risk–benefit ratio may take
several years, as was the case in January 2010 with
isotretinoine (Roaccutane®). An uncommon, yet serious
side effect of skin necrolysis associated with isotretinoine
use was identified; the discovery of this possible side effect
occurred 25 years after isotretinoine’s initial introduction.
A dilemma for regulators
This uncertainty surrounding the actual, everyday risks of a
medication’s use within an all-encompassing, general
population poses a dilemma for regulators. It is their job
to safeguard the public against harmful side effects by
thoroughly assessing the available data. Therefore, before a
new drug enters the market, an evaluation procedure occurs
to appraise safety data and effects, yet the tolerability of the
drug by a more extensive populace has yet to be
determined. Regulators prefer to not take risks, but at
times, this is unfortunately unavoidable; conversely, hin-
dering a medication’s market entry could be interfering with
a potentially life-saving treatment for some patients [3].
Every drug approval must go through this process of
weighing the benefits and the risks, considering that, at
times, those risks also include unknown outcomes that may
surface later [4].
Reactive reporting: pharmacovigilance
To quickly and efficiently gain knowledge surrounding the
lingering unknown safety data, post-marketing pharmaco-
vigilance programs have been developed in all European
Union (EU) countries. Healthcare professionals and, in
some countries patients as well, are asked to report any
unanticipated experience with a drug (including absence of
an anticipated beneficial effect). The offices involved in this
extended validation process confirm the unforeseen effects
from an epidemiological perspective. From there, the
results are forwarded to the pharmacovigilance database
operate by the World Health Organization (WHO)
Uppsala monitoring center. A better estimate of an actual
risk of using the medication is then assessed, keeping in
mind that these data reflect a more diversified patient
population [5]. Based on the frequency of a side effect,
how often it occurs (numerator), and the total known
exposure, the number of patients known to have been
treated in total (denominator), the results of the risk-
assessment is determined. This post-marketing process
proves extremely useful in helping to detect less common
side effects via mass collection. Although the pooling of
new data helps to clarify the medication’s risks when used
at large, not knowing the exact number of patients
exposed to the drug makes the “real” risk quantification yet
another approximation; albeit a more accurate appraisal than
was previously known [6].
Pro-active reporting: risk management and risk
minimisation
One of the responsibilities of the drug designers is to
consider side effects and risks that may occur after therapy
with their innovative product. Since November 2005, the
EMA (European Medicines Agency) has required a
proposed management plan for almost all medicines they
evaluate (exceptions are granted to some generic medica-
tions for which adequate safety data has already been
demonstrated). After approval, this becomes part of the
marketing license [7, 8].
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The post-authorisation safety studies (PASS) or “phase
IV studies” are intended to further detect side effects and
quantify data with increasing meticulousness and fervour.
They are completed by the marketing authorisation holder
(MAH), who is responsible for reporting a predefined, large
number of cases treated in everyday conditions. Phase IV
studies provide the opportunity to further develop factors
surrounding adverse effects: when, how and why they
occur.
For drugs with intrinsic safety risks, defined in this paper
as those with known adverse events associated with their
class or the pharmacological action, further steps must be
taken to minimise potential adverse effects in the patient
population. For these medications, the EMA requires the
applicant to submit another scheme in the form of a risk
minimisation plan. Herein, the precautionary actions that
have been taken to prevent patients from experiencing
known adverse effects of the drug are explained. These
adverse events can be either: a) those commonly seen in
select groups of predisposed patients or b) those directly
related to the pharmacological action of the drug in all
patients, such as those designed to treat diseases of the
blood and blood forming organs. The product erythropoi-
etin is an example of a drug classified under the latter
description. Simply stated, the goal of the risk management
plan is to proactively establish a product’s risk-benefit
analysis, which enables a healthcare professional to make
informed decisions.
Prescribing information is also dynamic and requires
regular updating. As new information unfolds, the pharma-
ceutical company may be requested to update the known
information for prescribers in the Summary of Product
Characteristics (SPC). Those with prescriptive authority are
encouraged to consult the latest version of the SPC available
prior to making pharmaceutical treatment decisions. The most
up-to-date reports about known side effects of a medicine
should be considered before prescribing, thus making careful
dating of the drug information essential for the protection of
patients against known risks. From this perspective, each
medicine has to be regarded as a work-in-progress.
The results of these pharmacovigilance activities
When such time, effort and money have been devoted to
assessing the safety data of an innovative medication, the
outcomes of these efforts are undoubtedly useful to inspect.
Post-marketing studies on drug safety policies and risk
management plans are scarce, but have begun to appear.
The results of one such study regarding biopharmaceuticals
indicated that the knowledge-base surrounding biologicals
is comprised primarily from clinically relevant side effect
data collected 7–8 years after market approval, not those
noted in pre-approval trials [9]. In this study the medi-
cations used were approved in the European Union from
1995 to 2007 and “clinically relevant side effects” were
considered to be those for which the prescribing informa-
tion had to be altered. This could be done via a “dear doctor
letter” or other direct communication with healthcare person-
nel.
Based on this study and others like it, the interpretation
of the data could be as follows: when a drug has been
marketed for 10 years or longer, the vast majority side
effects have surfaced [8–11]. Conversely, there are most
definitely cases where this proves not true [12]; however, in
both cases, risk management strategies for the whole life
cycle of a drug are of the utmost importance. Lastly,
historical evidence shows that changes in manufacturing
processes or source of raw materials at any stage of a
medicine’s development may cause numerous side effects
to present suddenly; this was exemplified during the case
with the adulterated heparin from China in 2009 [13].
These infrequent instances aside, it is encouraging to see
that pharmacovigilance programs do, indeed, play a crucial
role in disclosing the real-life safety profile of a drug
throughout its lifecycle.
Biosimilars
It is valid to view the development and evolution of new
pharmaceutical agents as an ongoing process. When a new
drug is first developed, patent protection usually extends for
approximately 20 years. On average, 8–10 of these are used
during the trials phases, leaving about 10–12 years of patent
protection once the drug is marketed. When the patent has
expired, competitors are allowed to produce medications
with the same active ingredient—generic versions. If the
copy-product meets quality criteria and pharmacokinetic
bioequivalence, the competing drug is allowed to enter the
market. This process has now occurred numerous times
again for a vast variety of small-molecule medications.
Recombinant DNA technology drugs are, however,
exceedingly more complex than small-molecule medicines.
As patents for the recombinant medications began to expire,
questions arose regarding the ability to produce duplica-
tions of these molecules exact enough to ensure patient
safety. Innovators, wishing to protect their trade secrets, did
not make available their production platforms (bacteria or
cell cultures). Thus, these had to be generated anew by the
competitor companies; a daunting task, indeed.
Moreover, the resulting product could not be precisely
identical on account of the many steps involved in the
downstream isolation, purification and subsequent formu-
lation of the product, among other reasons. Small discrep-
ancies would almost certainly occur and, even with
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achievement of the same pharmacological effect, the
discrepancies could possibly lead to new adverse drug
reactions (such as immunogenicity). Since these medicines
were (and are) very similar, but may not be exact copies,
the term “biosimilars” has been coined for these agents in
Europe (in the United States “follow-on biologic medicines”
is also used and in Canada “subsequent entry biologics”).
Eprex® and the PRCA case
The discussion surrounding the market entry of competitor
versions of recombinant medications was intensified followed
an unfortunate incident with Johnson & Johnson/OrthoBio-
tech. In 1998, a reformulation of the innovative erythropoietin
alpha product (Eprex®) was attempted. The original product
was made with human serum albumin as a solubiliser and
stabiliser. This ingredient was viewed by EU regulators as an
undesirable excipient to which improvement could be made
due to its potential to transmit bovine spongiform encepha-
lopathy (BSE) made. Following the nearly worldwide
introduction of the modified formulation, an increased rate
of pure red cell aplasia was noted. The incidences of this
immunological reaction against endogenous erythropoietin
were less frequent with other erythropoietin formulations,
including the non-modified Eprex® in the U.S. Correlations
where then made between the increased occurrences of this
once uncommon side effect and the new formulation of
Eprex®. Although the debate surrounding what specifically
was responsible for the immunological reaction has yet to be
solved, to many the lesson learned was undeniably transpar-
ent: manipulating the formulation may put patients at risk.
This case hastened the regulators to quickly address
pleas from the innovative industry—biotech products are
unique and require a different set of rules than that
applicable to small molecule/simple-chemical generics.
This was compatible with a process already addressed in
1996 and under development within Europe since 1998.
Through a refined regulatory system, the evaluation and
approval of competitive versions of recombinant medicines
was started.
In terms of how this affected market-entry of these
biosimilars, the unfortunate experiences with PRCA and
erythropoietin were pivotal. It was determined that bio-
similars also have the potential to cause to rare side effects
and would consequently be required to prepare risk
management guidelines prior to use [7]. This increase in
safety regulations accommodated the European Commis-
sion’s desire to safeguard patients against the unknown risks
that new copies of recombinant molecules. While the new
availability of highly specific medications at lower costs was
also highly beneficial to improving patient care in terms of
cost-savings.
The risk management system devised by EMA for new
medicines
Currently, an EURiskManagement Planmust be submitted to
the EMA as part of a marketing application for all new
chemical entities and biosimilars. This process began in
November 2005 and aimed to protect patients from harmful
events. By determining that the benefits of a medicine exceed
the risks by the greatest achievable margin, all patients are
safer. A risk management plan consists of two parts:
In part I, the safety profile of the medication is described
and pharmacovigilance activities proposed. Examples of
these activities include collecting of spontaneously reported
adverse events or post-authorisation safety studies. The
goal being the continuation of studying the safety concerns
of the medications following their usage in real-world
situations [9]. Part II should evaluate the necessity for risk
minimization activities and provide an action plan for each
potential safety concern. The legal requirements for these
plans are described in guidelines [7] and have recently been
reviewed [14]. Prescribers are able to read these drug
assessments created by the Committee for Medicinal
Products for Human Use (CHMP) and proposed risk
management plans. These documents are available in the
European Public Assessment Report (EPAR), on the
website of the EMA and via national drug licensing
authorities.
Adding further to the necessary complexities surround-
ing risk management plans, a distinction is made within the
plan itself between routine activities (i.e., being part of
good medical practice) and additional measures. Supple-
mentary measures can take many forms. Some examples
are: providing specific details in the prescribing information
(such as warnings), the production of educational leaflets,
establishment of a specialized training program, the
initiation of additional clinical studies, or planning long-
term follow-up of treated patients. The results of all these
extra activities must be included in confidential Periodic
Safety Update Reports (PSURs) to the EMA.
Lack of transparency
Despite of the huge amount of work that must go into the
preparation for and reporting of side effects, the process
still operates as a black box to the outside world. Drug
companies bear the formidable task of vigilantly reporting,
yet healthcare providers, including prescribing physicians,
do not have access to the actual risk management plans or
the reports they contain. Detailed safety information should be
a relevant factor when choosing to prescribe a drug. After
being provided safety data from the market authorisation
holders, the EMA internally analyzes and collects the safety
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reports in the PSURs; however, these are confidential docu-
ments, not accessible to outsiders. The French critical
medicines review journal La Revue Prescrire filed a
complaint on August 30, 2010 against the European
Medicines Agency (EMA), demanding increased transpar-
ency to medicines’ safety information and documentation.
EMA is now considering providing wider access to this kind
of documentation, beginning with specific requests for select
situations [15, 16].
The SIGNAL-publications from the Uppsala Monitoring
Centre of the WHO could provide another source of
information. These reports which contain the results of
post-marketing surveillance and other alerts are distributed
to national pharmacovigilance authorities and the relevant
pharmaceutical companies; yet they are, once again, not
accessible to healthcare providers. Frau et al. [8] discuss
similar concerns about the unavailability of the most
significant risk management plan data. Per Frau et al., in
minimum, the planned-pharmacovigilance-activities data
should be made publically available, including information
such as full-study protocols, clear timelines for their
development and the information regarding doctor and
patient programs [16].
Experiences with biosimilars in oncology
Historically
Two types of biosimilars of particular interest to the field of
oncology are filgrastim (G-CSF®) and erythropoietin.
Filgrastim is a relatively small protein drug (175 amino
acids, 19.6 kDalton) and has a strong safety record. It is a
drug considered to be relatively safe in terms of immuno-
genicity [17], but it has commonly been used in immuno-
compromised patients and, therefore, less immunogenic
responses are to be expected. When used outside this
populace, neutralising antibodies can occur. When these
antibodies are produced, the effectiveness of the drug is
compromised. This immunologic response is not always
easily detectible and makes the “normal” effects of G-
CSF® variable and a diverse range of outcomes possible.
As a result, the identification of clinically relevant differ-
ences between an unpredictable innovator product and the
biosimilar form of filgrastim is highly complex and the lack
of efficacy is not always obvious. Precautionary measures
have, thus, been taken within the licensing package for
filgrastim and other biosimilars. The responsibility to
monitor the occurrence of neutralising antibodies is listed
within the package and to do so is the job of the prescriber.
Currently available biosimilar filgrastim molecules have
been licensed by the EMA after comparison with Neup-
ogen® and are marketed by several companies under a
plethora of names. In order of EMA licensing, these are:
Filgrastim®, Ratiopharm®, Biograstim®, Ratiograstim®,
Tevagrastim®, Hexal®, Zarzio® and Nivestim®. Thus far,
these biosimilar agents have been used with predominantly
great success.
Erythropoietin is a larger and more complicated molecule
(165 amino acids with heavy glycosylation, resulting in a
molecular weight of 34 kDalton) and is used more frequently
than filgrastim in patients with active immune systems.
Resultantly, erythropoietin has the propensity to cause
immunologic reactions. As such, PCRA and other immune-
related adverse events are key issues to be included in the
required risk management plan. Immunogenicity, however, is
not a solitary concern with erythropoietin; additional side
effects relevant to this class of medications as a whole must
also be addressed for both innovator and competitive products
alike. Such class-common effects include consequences such
as hypertension and thromboembolic events, the latter of
which received particular attention in the field of oncology.
Oncologists struggled to help patients cope with the
anaemia and fatigue that often accompany cancer and
chemotherapy. They hoped that by occasionally adminis-
tering additional injections of erythropoietin, erythropoiesis
would be stimulated and blood transfusions could be
avoided. Unfortunately, undesirable sequalae were also
possible with two potential adverse outcomes of utmost
concern. First, the effect of erythropoietin had other
growth-stimulating properties, such as tumour growth.
Second, the incidence of venous thromboembolism and a
small unexplainable increase in mortality when anaemic
cancer patients were treated with epoetins [18].
The increased incidence of tumour-growth among eryth-
ropoietin users was hardly discernable and the studies
attempting to prove this effect contained sources of bias.
Addressing the second outcome of possible thromboembo-
lism, the increased incidence and mortality appeared to be
dose-dependent and would found to be rarely problematic if
the hemoglobin concentrations were not driven higher than
12 g/dl [19]. Nevertheless, these side effects have been the
subject of several studies and debates, both in Europe and
the US [20]. In an attempt to better protect patients via
openly displaying known safety data, the product informa-
tion of all epoetins—innovative and competitor alike—were
updated. The molecules currently approved by the EMA as
biosimilar forms of erythropoietin are: epoetin alfa (marketed
as Epoetin Alfa Hexal®, Abseamed® and Binocrit®); epoetin
theta (marketed as Eporatio® and Biopoin®) and epoetin zeta
(marketed as Silapo®).
Outcomes
The European Society of Medical Oncology (ESMO) has
created an evidence-based practice guideline [21, 22] from
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the currently available risks-and-benefits data on the use of
erythropoietin in cancer. Many of the negative outcomes
following the use of erythropoietin in cancer patients were
caused by the use of erythropoietin outside the approved
indications and/or recommended dosage [10, 23]. When
considering the use of erythropoietin in a patient with
cancer, it should be noted that erythropoietin does not
improve the outcome of the underlying disease; it is
considered to be supportive and is aimed at improving
only the quality of life, not mortality.
Outlook
The current experiences with the risk management of
biosimilars in oncology have not led to unsurpassable safety
concerns. These historical successes together with continuous
surveillance, provide a safe foundation for confident prescrib-
ing of these medicines. It can also be said that the EMA
regulators have put forth a solid effort to assure comparability
between innovator products and biosimilars.
Building from these historical events and experiences
with small molecules such as filgrastim and erythropoietin,
regulators face the next challenge ahead: biosimilar
monoclonal antibodies [24]. Monoclonal antibodies are
larger structures with between 1,000 and 1,500 amino acids
creating a mass of about 150 kDalton and comparability
exercises for biosimilar monoclonal antibodies will be
challenging [25]. In preparation, the EMA’s Similar
Biological Medicinal Products Working Party has drafted
two guidelines to inform the pharmaceutical industry how
the EMA plans to handle this new generation of biosimilars
[26, 27]. In the coming years, some patents of widely
prescribed monoclonal antibodies used in oncology will
begin to expire and guidelines such as these are paving the
way for biosimilar versions of these medicines.
Conclusion
With the population increasing, costs of medications rising
and treatment complexities intensifying, cost-escalation of
drug treatments is becoming unavoidable. With conven-
tional medicines, the use of competitive formulations is an
effective way to reduce costs while maintaining effective-
ness and access to drugs. For the more expensive protein
drugs, the European Union has designed a biosimilar
pathway to allow market access for competing versions of
these medications. Due to concerns about the comparability,
similarity and safety of these medicines, all biosimilars
shall follow a post-authorization risk management system.
This will help to inform regulatory authorities about the
effects of biosimilars under practice conditions in a large-
scale, diversified population. While transparency of the
information reported could be improved, until now, no new
or shocking findings have surfaced. Based on these
experiences, the currently licensed biosimilars can be seen
as equally efficacious and safe as innovator products when
making prescribing decisions. With patents for monoclonal
antibodies are expiring, we can look confidently ahead to
the approval and introduction of a new generation of
biosimilars.
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